Effects of Variable Doses of Neurokinin B on Hematological and Coagulation    Parameters in Adult Male Rats

Faiqah Ramzan; Tahira Atta; Muhammad Waqas Luqman; Muhammad Haris  Ramzan

doi:10.51253/pafmj.v74i5.12328

Authors

Faiqah Ramzan Department of Animal and Poultry Production, Faculty of Veterinary and Animal Sciences (FVAS), Gomal University, Dera Ismail Khan Pakistan
Tahira Atta Khyber Medical University Institute of Medical Sciences Pakistan
Muhammad Waqas Luqman Khyber Medical University Institute of Medical Sciences Pakistan
Muhammad Haris Ramzan Khyber Medical University Institute of Medical Sciences Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.12328

Keywords:

Activated partial thromboplastin time, Blood coagulation, Blood coagulation tests, Neurokinin b, Platelets, prothrombin time, Tachykinins

Abstract

Objective: To evaluate the dose-dependent effects of Neurokinin B on hematological and coagulation parameters in adult male Sprague Dawley rats.

Study Design: Laboratory-based experimental study

Place and Duration of Study: Gomal University and KMU Institute of Medical Sciences from February 2019 to April 2021.

Methodology: Adult male Sprague Dawley rats (n=5 per group) were administered intraperitoneally with Neurokinin B at doses of 1 µg, 1 ηg and 1 ρg for 12 days consecutively. Control rats received distilled water injections. After 12 days, rats were sacrificed, and blood samples were collected from the left ventricle for hematological and coagulation analysis.

Results: Bleeding time was significantly prolonged in NKB-µg (114±17.10sec) and Neurokinin B -ηg (72±22.25sec) compared to control (33±12.55sec). Clotting time (CT) was also increased (NKB-µg: 111±17.10sec; NKB-ηg: 69±17.10sec, control: 42±12.55sec), as did prothrombin time (PT) [NKB-µg: 93.60±10.92sec; NKB-ηg: 63.40±12.66sec, control: 15±4.12sec] and activated partial thromboplastin time (APTT) [NKB-µg: 94.80±14.04sec; NKB-ηg:68.60±13.74sec, control: 19.40±2.97sec]. Additionally, mean platelet volume [NKB-µg:8.94±0.36fl, control: 8.04±0.48fl] and leukocyte count (×103/µl) [NKB-µg: 12.14±0.69, control: 8.87±1.32] were significantly increased in NKB-treated animals compared to control. There was a significant increase in international normalized ratio in NKB-µg (6.86±0.80) and NKB-ηg (4.65±0.93) compared to control group (1.10±0.30). Conversely, platelet count (×103/µl) was decreased significantly in NKB-µg group (787.80±48.51) compared to the control group (960.60±58.71).

Conclusion: NKB administration led to leukocytosis, thromboctopenia, and affected coagulation pathways with prolonged BT, CT, PT, APTT and INR dose-dependently.

Downloads

Download data is not yet available.

References

Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11(15): 2045-2081. https://doi.org/10.2174/0929867043364748

Page NM, Woods RJ, Gardiner SM, Lomthaisong K, Gladwell RT, Butlin DJ, et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia. Nature 2000; 405(6788): 797-800. https://doi.org/10.1038/35015579

Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009; 41(3): 354-358. https://doi.org/10.1038/ng.306

Young J, Bouligand J, Francou B, Raffin-Sanson ML, Gaillez S, Jeanpierre M, et al. TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. J Clin Endocrinol Metab 2010; 95(5): 2287-2295. https://doi.org/10.1210/jc.2009-2600

Ruiz-Pino F, Garcia-Galiano D, Manfredi-Lozano M, Leon S, Sánchez-Garrido MA, Roa J, et al. Effects and interactions of tachykinins and dynorphin on FSH and LH secretion in developing and adult rats. Endocrinology 2015; 156(2): 576-588. https://doi.org/10.1210/en.2014-1026

Skorupskaite K, George J, Anderson RA. Role of a neurokinin B receptor antagonist in the regulation of ovarian function in healthy women. Lancet 2015; 385 (Suppl 1): S92.

https://doi.org/10.1016/s0140-6736(15)60407-x

Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. J Clin Endocrinol Metabol 2017; 102(10): 3647-3661.

https://doi.org/10.1210/jc.2017-01138

Brain SD. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology 1997; 37(2): 133-152. https://doi.org/10.1016/S0162-3109(97)00055-6

Graham GJ, Stevens JM, Page NM, Grant AD, Brain SD, Lowry PJ, et al. Tachykinins regulate the function of platelets. Blood 2004; 104(4): 1058-1065.

https://doi.org/10.1182/blood-2003-11-3979

Bost KL. Tachykinin-mediated modulation of the immune response. FBL 2004;9(6):3331-3332.

https://doi.org/10.2741/1484

Feng F, Yang J, Tong L, Yuan S, Tian Y, Hong L, et al. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol Int 2011; 35(6): 623-629. https://doi.org/10.1042/CBI20100229

Jones S, Tucker KL, Sage T, Kaiser WJ, Barrett NE, Lowry PJ, et al. Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood 2008; 111(2): 605-612. https://doi.org/10.1182/blood-2007-07-103424

Mahmood R, Mahmood A, Khan M, Ali S, Khan SA, Jaffar SR. Rare bleeding disorders: spectrum of disease and clinical manifestations in the Pakistani population. BR 2020; 55(3): 146-150. https://doi.org/10.5045/br.2020.2020035

European Animal Research Association. EU regulations on animal research London, England: European Animal Research Association; Available from: https://www.eara.eu/animal-research-law [Accessed on November 28, 2022]

Jy W, Bidot CJ, Jr., Nunez S, Johansen ME, Horstman LL, Ahn YS. Red Cell-Derived Microparticles (RMP) As Hemostatic Agent: Evaluation in a Rabbit Ear Bleeding Model. Blood 2012; 120(21): 2238-2238.

https://doi.org/10.1182/blood.V120.21.2238.2238

Laffan MA, Manning RA. 18 - Investigation of Haemostasis. In: Bain BJ, Bates I, Laffan MA, editors. Dacie and Lewis Practical Haematology (Twelfth Edition): Elsevier; 2017. p. 366-409.

https://doi.org/10.1016/B978-0-7020-6696-2.00018-7

Watson H, Culligan D, Manson L. Haematology and transfusion medicine. In: Penman ID, Ralston SH, Strachan MWJ, Hobson R, editors. Davidson's Principles and Practice of Medicine. 24th ed. London, UK: Elsevier; 2023. p. 921-988.

Lv B, Guo FF, Lin JC, Jing F. Efficacy and safety of argatroban in treatment of acute ischemic stroke: A meta-analysis. World J Clin Cases 2022; 10(2): 585-593.

https://doi.org/10.12998/wjcc.v10.i2.585

Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% Sodium Citrate Concentration on Routine Coagulation Testing. Am J Clin Pathol 1997; 107(1): 105-110.

https://doi.org/10.1093/ajcp/107.1.105

Levin J, Bessman JD. The inverse relation between platelet volume and platelet number. Abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. J Lab Clin Med 1983; 101(2): 295-307.

Castelli R, Cassinerio E, Cappellini MD, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Dis Drug Target 2007;7(3): 153-162.

https://doi.org/10.2174/187152907781745251

Verheul HM, Pinedo HM. The importance of platelet counts and their contents in cancer. Clin Cancer Res 2003; 9(9): 3219-3221.

Letai A, Kuter DJ. Cancer, Coagulation, and Anticoagulation. Oncologist 1999; 4(6): 443-449.

https://doi.org/10.1634/theoncologist.4-6-443

Jones S, Gibbins JM. The neurokinin 1 receptor: a potential new target for anti-platelet therapy? Curr Opin Pharmacol 2008; 8(2): 114-119. https://doi.org/10.1016/j.coph.2008.01.004

Brunelleschi S, Tarli S, Giotti A, Fantozzi R. Priming effects of mammalian tachykinins on human neutrophils. Life Sci 1991; 48(2): PL1-PL5. https://doi.org/10.1016/0024-3205(91)90416-9